UPDATE: Webush Upgrades Ironwood Pharmaceuticals on Completed Financing

In a report published on Thursday, Wedbush analyst Gregory R. Wade Upgraded Ironwood Pharmaceuticals (NASDAQ: IRWD ) from Underperform to Neutral and maintained a price target of $12 on the company on recently completed financing and Linzess script metrics. In the report, Wedbush stated, "While IRWD shares could benefit in